DOCSLIB.ORG

Speaker Bios

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Speaker Bios COVID-19 Lessons to Inform Pandemic Influenza Response Public Workshop May 21, 2021 Day 2 Speaker Biographies Ben Adeiza Adinoyi, MBBS, MPH, is a Public Health Physician with close to 20 years of experience in the design and execution of a broad range of health programmes in African countries. Dr. Adinoyi practiced clinical medicine across various health institutions both in Nigeria and outside Nigeria amongst which are the Nigerian Armed Forces Reference Hospital, Ahmadu Bello University Teaching Hospital, Kogi state University Teaching Hospital, Atacora Donga Regional Hospital in Benin Republic. He has focused primarily on Public Health at the international level for the past 13 years. He is currently the Head of Africa Regional Health and Care Unit at the International Federation of Red Cross and Red Crescent Societies. Dr. Adinoyi earned an MBBS degree from Ahmadu Bello University in Nigeria and MSc Public Health from London School of hygiene and Tropical Medicine, Masters in Leading Innovation and Change from York St John University and a Master’s in Health Research from Lancaster University. He is also a Certified Balanced Score Card strategist from the George Washington University. He is currently undertaken Doctoral Research with a focus on barriers and facilitators of telemedicine adoption in sub- Saharan Africa. Phionah Atuhebwe, MPH, MBBS, is an experienced vaccinologist and immunisation expert, as well as a sexual and reproductive health specialist with a demonstrated history of International Project Management in the Public Health Sector. She is currently the New Vaccines Introduction Medical Officer at the World Health Organisation (WHO) Regional Office for Africa in Brazzaville, Congo. She coordinates the WHO’s work in the African region to introduce new vaccines and increase uptake of underutilized vaccines. Dr. Atuhebwe is currently chairing the vaccines pillar for the COVID-19 Pandemic response Incident Management Support Team for WHO in the African Region. She previously worked with PATH supporting new vaccine introductions in Africa and South East Asia. She holds a Bachelors degree in Medicine and Surgery from Mbarara University, Uganda; a Masters degree in International Public Health from the University of Leeds, United Kingdom; postgraduate training in Vaccinology from University of Cape Town, South Africa; Project leadership and Management from Cornell University, USA Paula Barbosa, Ph.D., MSc, joined IFPMA in October 2016 as Vaccines Policy Manager and is responsible for the IFPMA Influenza Vaccine Supply International Task Force, as well as vaccine regulatory and programmatic policy, norms and standards. Paula holds a MSc in Global Health Policy from the London School of Hygiene and Tropical Medicine, and a PharmD in Pharmaceutical Sciences from the University of Porto, PortugaL Prior to joining IFPMA, Paula had worked for GlaxoSmithKline (GSK) Vaccines in different global marketing and commercial roles, and in GSK Rare Diseases Business Unit in a market access function covering the Latin American region. Rodrigo Cruz. Ph.D., graduated in Civil and Environmental Engineer from the University of Brasília (2005), graduated in Law from the Centro Universitário de Brasília (2007). Master's and doctorate in Transport Engineering from the University of Brasília (2008 and 2013). Served as Project Manager at the Department of Planning and Studies of the Civil Aviation Secretariat of the Presidency of the Republic. Had a career in the public sector as Infrastructure Analyst and held the position of Deputy Executive Secretary of the Ministry of Infrastructure. In this Ministry, Cruz was known to have coordinated the operation to bring 960 tons of masks, tests, and supplies from China at the beginning of the Pandemic, in 44 flights made in April 2020. He was appointed Executive Secretary of the Ministry of Health on 03/30/21. Rob Handfield, Ph.D., is the Bank of America University Distinguished Professor of Supply Chain Management at North Carolina State University, and Director of the Supply Chain Resource Cooperative (http://scm.ncsu.edu/). Handfield is considered a thought leader in the field of supply chain management, and is an industry expert in the field of strategic sourcing, supply market intelligence, and supplier development. He has spoken on these subjects across the globe, including China, Azerbaijan, Turkey, Latin America, India, Europe, Korea, Japan, Canada, in multiple presentations and webinars. Handfield has published more than 120 peer reviewed journal articles and is regularly quoted in global news media such as the Wall Street Journal, Bloomberg, NPR, the Financial Times, the San Francisco Chronicle, and CNN. He has recently published article on the shortage of PPE in the Harvard Business Review and the Milbank Quarterly Journal. Rasmus Bech Hansen, MPA, is the co-founder and CEO of Airfinity, one of the world's leading providers of real time predictive vaccine intelligence. He has been quoted in The Lancet and Nature and his company's predictions are relied upon by leading news organisations such as the Financial times, Bloomberg and The Washington Post. Airfinity was among the first to highlight the global divergence in vaccination supply, funding and development. He is a board member of the newspaper group, Information.dk. Rasmus holds an MPA from Harvard University and is a recipient of the Crown Prince Frederic award for excellent scholarship. He lives in London. Nagwa Hasanin, Ph.D., currently serves as Senior Advisor, Health for UNICEF’s supply division, where she links programmatic and supply preparedness efforts for a range of disease-epidemiological scenarios and emergencies so that UNICEF is best positioned to respond to emerging health threats with existing supply tools as well as state of the art product innovations by supporting research and development efforts. Dr. Hasanin is an immunologist and molecular biologist science graduate from Cairo University. Her specialization and PhD was awarded in 1994 from Cairo University in Egypt in collaboration with State University in Buffalo, NY, and the USAID Schistosomiasis Research Project in Cairo. She also held a post-doctoral fellowship in cancer immunology at Henri Mondor University hospital in Paris from 1996- 1999 and had worked work in diverse settings (ministry of health and private sector in addition to UN organization) supporting vaccine research and immunization program and health emergencies. Richard Hatchett, M.D., is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership of public, private, philanthropic and civil organizations that supports the development of vaccines against high priority public health threats and technology platforms to allow the rapid development of vaccines against emerging infectious diseases such as COVID-19. Dr. Hatchett was previously the acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA) and served as Director of Medical Preparedness Policy on the Homeland and National Security Councils under Presidents Bush and Obama, respectively. He received his medical degree from Vanderbilt University and completed clinical training in internal medicine and medical oncology at Cornell and Duke Universities. David Kaslow, M.D., serves as PATH’s Chief Scientific Officer, supporting PATH’s Drug Innovation and Access Initiative and PATH’s Center for Vaccine Innovation and Access (CVIA). As CVIA Head, David leads PATH’s work to advance immunization equity and vaccination coverage to reduce vaccine- preventable diseases through increasing and improving affordability, availability, acceptability, and sustainability of essential existing and new vaccines for routine immunization and pandemic/epidemic preparedness and response, particularly for those living in the lowest resources. His 35+ years of experience in product development and introduction include serving in the US government (US Public Health Service, NIH/NIAID), biotech (Vical), multi-national pharma (Merck Research Laboratories), and non-profit (PATH) sectors. David also serves on a number of advisory committees, including WHO’s Product Development of Vaccines Advisory Committee (PDVAC). David received a B.S. in biochemistry from University of California, Davis, and a M.D. from University of California, San Francisco. Marie Mazur, Pharm. D. Appointed in 2020, Marie provides leadership on the development and execution of Ready2Respond’s goals and actions, while optimizing cross-sector partnerships to ensure cost-effective implementation of identified initiatives. Marie brings more than 20 years of experience in the vaccine industry. Prior to joining Ready2Respond, she headed up the global Pandemic Response Solutions unit for Seqirus, a CSL Company. In 2018-2019, Marie was Co-Chair of the Bio-Defense Policy Advisory Committee at the Biotechnology Innovation Organization. Marie is member of the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI), a program of The Task Force for Global Health. Marie received her doctorate in Pharmacy, and her master’s degree in Regulatory Affairs, from Paris University in France. She is also a graduate from INSEAD Business School. Mark McKinlay, Ph.D., is Director for the Center for Vaccine Equity (CVE) based at the Task Force for Global Health. CVE programs include the Polio Eradication Surge Capacity Support team, Polio Antivirals Initiative, Partnership for Influenza Vaccine Introduction (PIVI),
Load more

Recommended publications
  • Report on the Strategic Response to COVID-19 in the WHO African Region
    Report on the Strategic Response to COVID-19 in the WHO African Region February – December 2020 Report on the Strategic Response to COVID-19 in the WHO African Region February to December, 2020 © WHO Regional Office for Africa 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific or- ganization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following dis- claimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Report on the Strategic Response to COVID-19 in the WHO African Region, February to December, 2020. Li- cence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Africa Is Waging a War on COVID Anti-Vaxxers
    news feature Prospective recipients of a vaccine against COVID-19 waited to be called from under a shed at a public vaccination site in Nigeria’s southwest city of Ibadan. Credit: Paul Adepoju / Nature Medicine Africa is waging a war on COVID anti-vaxxers Misinformation about COVID-19 vaccines often starts life in Europe or the United States but has found fertile ground in Africa, which poses a challenge for local health leaders. Paul Adepoju hade is a 58-year-old Nigerian So many uncertainties made me doubt expressed doubt about the vaccination,” frontline health worker living with whether I really need the vaccine,” she tells says Roger Tatoud, deputy director for Sosteoarthritis. She is also overweight, Nature Medicine. HIV Programmes at the International diabetic and hypertensive, all of which Shade is not the only frontline health AIDS Society. made her first in line for a vaccine against worker to refuse a vaccine against Whether or not to receive a vaccine is COVID-19 when it finally became available COVID-19, despite its availability. a person’s individual decision, but vaccine in Nigeria. Her eldest daughter booked an hesitancy may prevent herd immunity from appointment for her at their local primary Africa’s anti-vaxxers being reached, especially in sub-Saharan healthcare center, but when the day came to Vaccine hesitancy is a phenomenon that Africa, where vaccine doses are sparingly receive her first dose of the vaccine against predates COVID-19. A 2015 report by the available and the anti-vaccine campaign has COVID-19, she changed her mind.
    [Show full text]
  • Weekly COVID-19 Pandemic Briefing – Experience and Response in Africa
    Transcript Webinar: Weekly COVID-19 Pandemic Briefing – Experience and Response in Africa Professor David Heymann CBE Distinguished Fellow, Global Health Programme, Chatham House, Executive Director, Communicable Diseases Cluster, World Health Organization (1998-2003) Dr John Nkengasong Director, Africa Centers for Disease Control and Prevention (Africa CDC) Chair: Emma Ross Senior Consulting Fellow, Global Health Programme, Chatham House Event date: 03 June 2020 The views expressed in this document are the sole responsibility of the speaker(s) and participants, and do not necessarily reflect the view of Chatham House, its staff, associates or Council. Chatham House is independent and owes no allegiance to any government or to any political body. It does not take institutional positions on policy issues. This document is issued on the understanding that if any extract is used, the author(s)/speaker(s) and Chatham House should be credited, preferably with the date of the publication or details of the event. Where this document refers to or reports statements made by speakers at an event, every effort has been made to provide a fair representation of their views and opinions. The published text of speeches and presentations may differ from delivery. © The Royal Institute of International Affairs, 2020. 10 St James’s Square, London SW1Y 4LE T +44 (0)20 7957 5700 F +44 (0)20 7957 5710 www.chathamhouse.org Patron: Her Majesty The Queen Chair: Jim O’Neill Director: Dr Robin Niblett Charity Registration Number: 208223 2 Webinar: Weekly COVID-19 Pandemic Briefing – Experience and Response in Africa Emma Ross Good morning, and thank you for joining us for this week’s Chatham House COVID-19 briefing with Chatham House Distinguished Fellow, David Heymann, who, as many of you know, is a renowned expert on outbreak control, who spearheaded the global response to the SARS outbreak in 2003.
    [Show full text]
  • Toward a Global Pathogen Early Warning System: Building on the Landscape of Biosurveillance Today
    TOWARD A GLOBAL PATHOGEN EARLY WARNING SYSTEM: BUILDING ON THE LANDSCAPE OF BIOSURVEILLANCE TODAY JULY 2021 By Dr. Natasha E. Bajema, William Beaver, and Christine Parthemore With contributing authors Dr. Adejare Atanda, Dr. Joanne Horn, Dr. David Manheim, Dr. Daniel Regan, Sid Sharma M.D., Dr. Jacob Swett, and Dr. Nikki Teran. Edited by Christine Parthemore and Francesco Femia. an institute of an institute of This report should be cited as: “Toward a Global Pathogen Early Warning System: Building on the Landscape of Biosurveillance Today.” A product of the Janne E. Nolan Center on Strategic Weapons, an institute of the Council on Strategic Risks. Authors: Natasha Bajema, Bill Beaver, Christine Parthemore, Adejare Atanda, Joanne Horn, David Manheim, Daniel Regan, Sid Sharma, Jacob Swett, and Nikki Teran. Edited by Christine Parthemore and Francesco Femia. July 2021. © 2021 The Janne E. Nolan Center on Strategic Weapons, an institute of The Council on Strategic Risks Cover Photo: In Vietnam, a nurse administering flu vaccine to young boy. ATHIT PERAWONGMTHA / CDC GLOBAL. CONTENTS 4 EXECUTIVE SUMMARY 7 PART I: INTRODUCTION 11 PART II: CREATING A GLOBAL EARLY WARNING SYSTEM 13 ADVANCING EARLY WARNING 16 LEVERAGING A NEW LANDSCAPE OF TECHNOLOGICAL SOLUTIONS 25 PART III: THE LANDSCAPE TODAY 26 DIVERSE SYSTEMS ACROSS THE UNITED STATES 34 EXAMPLES OF SYSTEMS AROUND THE WORLD 48 COVERING THE FULL RANGE OF BIOLOGICAL THREATS 49 PART IV: NEXT STEPS 53 ENDNOTES 59 ANNEX 60 INTRODUCTION 61 VIGNETTE #1: COVID-19, 2019-PRESENT 75 VIGNETTE #2: SEVERE ACUTE RESPIRATORY SYNDROME (SARS), 2002-2004 80 VIGNETTE #3: H5N1 AVIAN INFLUENZA, 2003 TO PRESENT 86 VIGNETTE #4: EBOLA, 2013-PRESENT 90 VIGNETTE #5: MOSQUITO-BORNE PATHOGENS: ZIKA, WEST NILE, AND MALARIA 95 CONCLUSION 96 ENDNOTES The Janne E.
    [Show full text]
  • COVID Africa Nigelhalls
    SUPPORTING SOCIAL WORK IN MALAWI (SSWIM): CONTRIBUTION TO IFSW AFRICA WEBINAR 6 MAY 2020 (NIGEL HALL) COVID-19 Africa: Social Work Practice, Ethical Dilemmas and Human Rights Concerns HUMAN RIGHTS & ETHICS IN SOCIAL WORK IFSW’s ethical statement underlines the importance of promoting human rights which stresses that social work is based on respect for the inherent worth, dignity of all people and the individual and social /civil rights that follow from this challenging discrimination and oppression promoting social justice, respecting diversity work toward access and the equitable distribution of resources challenge unjust policies and practices build networks of solidarity to work toward transformational change and inclusive and responsible societies. HUMAN RIGHTS IN AFRICA The African Commission on Human and Peoples’ Rights based in Addis has called for governments to put human rights at the centre of their fight against Covid-19. The African Centres for Disease Control (CDC) recorded on 6 May 2020 there were 49,352 cases, 1959 deaths and 16,315 recoveries. Recently it has urged States Parties to ensure that COVID-19 responses are designed and implemented in a way, which respect fundamental human rights and which do not lead to persecution and violence towards vulnerable groups. From our previous webinar we learned about the contribution that social workers are making already, all of which are key human rights roles for the profession: psycho-social support to those living under the lockdown helping in situations of domestic
    [Show full text]
  • WEBINAR Strategies to Improve COVID-19 Vaccines Uptake In
    Strategies to improve COVID-19 vaccines uptake in COMESA Member States: Lessons learnt 4th - 5th August 2021 WEBINAR #COVIDvaccines #VaccinesWork #CovidVaccineSavesLives #CovidVaccineRollOutCOMESA Introduction The advent of the COVID-19 towards the end of 2019, and its subsequent fast spread across the world has caused countries to impose travel restrictions and lockdowns among other measures to contain the spread of the virus. The deaths caused by the virus have been mounting. Fortunately, several leading medical institutions have developed vaccines for the virus. However, African countries have had differing experiences in the uptake of the vaccines. Thus, the Africa Centres for Disease Control (CDC) in collaboration with COMESA has identified the need to create public awareness and sensitization on COVID-19 vaccines among its Member States. Subsequently, a two-day webinar for the 21 COMESA Member States will be conducted on 4th and 5th August 2021. Objective of the Webinar To conduct a webinar on strategies to improve COVID-19 vaccine uptake in COMESA Member States through experience sharing. Specific Objectives ● Identify possible reasons behind slow uptake of the vaccines by some COMESA Member States. (Analyse the response of 5 surveys question on vaccines hesitancy ● Strengthen strategies to improve COVID-19 vaccine uptake in COMESA Member States ● Strengthen experience sharing among COMESA Member States on COVID-19 vaccine rollout. Expected Outputs: ● Reasons and causes of the low uptake of vaccine in the Member States identified ● Enhanced capacity of COMESA Member States to increase COVID-19 vaccine uptake in their countries ● Strengthened interactions between the COMESA Member States on the COVID-19 response and vaccine.
    [Show full text]
  • Report “A Global Deal for Our Pandemic Age”
    A GLOBAL DEAL FOR OUR PANDEMIC AGE REPORT OF THE G20 HIGH LEVEL INDEPENDENT PANEL A GLOBAL DEAL FOR OUR PANDEMIC AGE Report of the G20 High Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response June 2021 www.pandemic-financing.org A Global Deal for Our Pandemic Age: Foreword The High Level Independent Panel was asked by to ensure that large swathes of the world’s the G20 in January 2021 to propose how finance population are not left ill-equipped to respond can be organized, systematically and sustainably, to when a pandemic strikes, is in the mutual interests reduce the world’s vulnerability to future pandemics1. of all nations, not only a humanitarian imperative in its own right. Our report sets out critical and actionable solutions and investments to meet the challenge of an age of In short, we need a global deal for our pandemic pandemics, and to avoid a repeat of the catastrophic age. We must strengthen global governance and damage that COVID-19 has brought. The Panel mobilize greater and sustained investments in arrived at its recommendations after intensive global public goods, which have been dangerously deliberations and consultations with a wide range underfunded. Both are critical to building resilience of stakeholders and experts around the globe against future pandemics. over a period of four months. We urge that our proposals be discussed, developed further, and It requires establishing a global governance and implemented as a matter of urgency. financing mechanism, fitted to the scale and complexity of the challenge, besides bolstering Scaling up pandemic preparedness cannot wait the existing individual institutions, including the until COVID-19 is over.
    [Show full text]
  • Africas Vaccine Manufacturing for Health Security
    VIRTUAL CONFERENCE: AFRICA'S VACCINE MANUFACTURING FOR HEALTH SECURITY Monday 12th & Tuesday 13th April 2021 Master of Ceremonies Opening Session: Mr Stepples Muchimba, Ag Director, African Union Commission Sessions 2-11: Mr Chaacha Mwita, Consultant, Health Communication AFRICA'S VACCINE MANUFACTURING FOR HEALTH SECURITY Monday 12th & Tuesday 13th April 2021 DAY 1: MONDAY 12TH APRIL TIME (EAT) SESSION AGENDA SPEAKER TITLE OPENING Welcome remarks HE Moussa Faki Mahamat Chairperson, African Union Commission, Ethiopia Opening remarks HE Félix Antoine Tshilombo Tshisekedi Chairperson, NEPAD Heads of State and Government Orientation Committee Remarks HE Matamela Cyril Ramaphosa President, Republic of South Africa and African Union Champion for COVID-19 President, Republic of Rwanda and Chairperson, NEPAD Heads of State and Remarks HE Paul Kagame Government Orientation Committee Hon Mr Abdoulaye Diouf Sarr, Remarks on behalf of HE Macky Sall President of Minister of Health and Social Action, Republic of Senegal the Republic of Senegal Remarks HE Wamkele Mene Secretary-General, African Continental Free Trade Area Secretariat, Ghana SESSION I: 1:00-2:00 PM Opening Remarks HE Dr Ibrahim Assane Mayaki Chief Executive Officer, AUDA-NEPAD, South Africa REMARKS BY PARTNERS Remarks Dr Tedros Adhanom Ghebreyesus Director-General, World Health Organization, Geneva Remarks Dr Ngozi Okonjo-Iweala Director-General, World Trade Organization, Geneva United Nations Under-Secretary-General and Executive-Secretary, Economic Remarks Dr Vera Songwe Commission
    [Show full text]
  • Pathogen Surveillance Report to the UK G7 Presidency 2021
    A proposal to develop an equitable global pathogen surveillance network in 2021 that can prevent and respond to emerging and endemic infectious diseases at speed and at scale This report has been written by Sir Jeremy Farrar, Director of Wellcome, at the request of the UK Presidency of the G7. It draws on contributions from a large number of practitioners and global health experts. A full list is set out at the end of the document. EXECUTIVE SUMMARY 1. The development and utilisation of pathogen surveillance at scale and its integration in real time with classical public health, epidemiology, genomics, research, clinical medicine and allied data has been one of the success stories of the COVID-19 response in some parts of the world. 2. The COVID-19 experience and those of previous epidemics, (Nipah, SARS-CoV1, H5N1, MERS, Ebola, Zika, H1N1, cholera, C. difficile, other multi-drug resistant infections etc), demonstrate the imperative of integrating and funding classical public health, clinical medicine and the research and academic communities with these new technologies, through an equitable global partnership. 3. Once established, this global partnership would help identify new variants of SARS-CoV2 and pre-emergent zoonotic coronaviruses and provide invaluable resources for the rapid development of diagnostics and countermeasures (public health measures as well as drugs and vaccines). The creation of this global partnership would enable the detection and full characterisation (genotype, phenotype, clinical and epidemiological features) of current and future epidemics involving known and emerging infections before they become pandemics. 4. The partnership would have continuous and cost-effective utility by providing surveillance of endemic infections.
    [Show full text]
  • Minutes of Board Meeting #14 Video/Teleconference
    Minutes of Board meeting #14 Video/Teleconference 11.30-14.30 GMT, 24-25 June 2021 Board members Observers • Jane Halton, Chair of the Board Investors council • Cherry Kang, Christian Medical College Vellore, • Austria: Norbert Feldhofer Vice-Chair of the Board • Canada: Jennifer Lai • Jeremy Farrar, Wellcome Trust (Day 1-From 11.50- • Ethiopia: Abebe Genetu 12.40pm; Charlie Weller, Delegate Day 1-From • Finland: Outi Kuivasniemi 12.40pm) • Gates Foundation: Hanna Cameron • Nadine Gbossa, International Fund for Agricultural • Germany: Kerstin Kaempf Development • Japan: Taguchi Okubo (Day 1); Kazuho Taguchi • Veronika von Messling, Federal Ministry of (Day 2) Education and Research • Malaysia: Mohd Redzuan • Ichiro Kurane, Ministry of Health Labour and • Mexico: Ambassador Ulises Canchola Welfare, Japan • New Zealand: Peter Bartlett • John Nkengasong, Africa CDC (Day 1-From 12.45pm) • Norway: Maha-Noor Khan • David Reddy, Medicines for Malaria Venture • UK: Sarah Legrand • Peter Piot, London School of Hygiene & Tropical • Wellcome Trust: Charlie Weller (IC chair) Medicine (Esme Mroz-Dawes, Delegate Day 1-From 12.40pm) • Rajeev Venkayya, Takeda • USAID: Tracey Goldstein • Charlotte Watts, UK Department for International • Korea: Seung Yeon Lee Development (Day 1-From 11.50-12.58pm/From • Indonesia: Penny Herasati 13.40pm; Day 2- From 12.20pm) • Saudi Arabia: Hani Jokhdar Non-voting members Management • Richard Hatchett, CEO CEPI • Mads Høgholen • Peggy Hamburg, JCG Chair (Day 2-From 12.40pm) • Frederik Kristensen • Helen Rees, SAC Chair
    [Show full text]
  • Vol. 25, No. 1, 2021
    The Publication on AIDS Vaccine Research WWW.IAVI.ORG/IAVI-REPORT | VOLUME 25, ISSUE 1 | JUNE 2021 A tale of two pandemics: HIV and COVID FROM THE EDITOR The last time I penned a letter in this publication, nearly In this issue, I spoke with Dr. John Nkengasong, director of a year ago, I closed by saying: “If science is our best hope, the Africa Centres for Disease Control and Prevention, on we are in good hands.” the slow rollout of COVID vaccines in Africa and how he thinks the continent should prepare for future pandemics. That certainly proved to be the case. There are now three authorized COVID-19 vaccines in the U.S., and seven that Other voices featured in this issue are those of four have received an Emergency Use Listing by the World Health leading HIV researchers who are lending the knowledge Organization, which is a prerequisite for the vaccines being and experience they’ve honed over the now four decades eligible for global distribution though the COVAX facility. of HIV/AIDS work to COVID vaccine research. Their The speed with which these vaccines were developed, and efforts are inspiring. how effective they are at preventing severe disease and, in many cases symptomatic infection altogether, is a truly It isn’t news to our readers that developing an HIV impressive illustration of the power of science. vaccine is a far more difficult challenge than developing COVID vaccines. But there is some good news: scientists In countries with high vaccination rates, SARS-CoV-2 are making progress on the arduous path to triggering infection rates are largely plummeting.
    [Show full text]
  • Policy Insights 98
    Policy Insights 98 November 2020 US and Chinese COVID-19 Health Outreach to Africa and Latin America: A Comparison PAULO ESTEVES & COBUS VAN STADEN African perspectives Global insights Executive summary The impact of the COVID-19 pandemic has arguably been worsened by the lack of a coordinated global response, driven in part by the tensions between the US and China. On a wider scale, the pandemic has also driven a nationalist turn that undercuts regional and multilateral approaches. This policy insight tracks these trends, and shows how the pandemic has strengthened pre-existing trends away from globalisation. However, even in this divided field, international outreach has played an important role in mitigating the impact of the pandemic. A comparison is drawn between the outreach by China and by the US to Africa and Latin America. While the US has depended largely on its earlier initiatives, China has committed significant new resources to the COVID-19 fight. Both sides have tried to use these measures to gain diplomatic ground, with especially China drawing on a wide range of state and non-state actors. Introduction The COVID-19 pandemic has been an unprecedented challenge to healthcare systems globally. Medical institutions in both the developed and developing worlds have come under massive strain owing to the large number of confirmed cases and the increased pressure for testing. The pandemic has also stretched the organisational capacity of national and transnational health authorities. However, the impact of the COVID-19 pandemic reaches far wider than healthcare. It has triggered the largest economic crisis since the Great Depression, and kicked off a related debt crisis in large parts of the Global South.
    [Show full text]